TNFRSF13C and plasma cell myeloma: Collectively, we show that BAFF-R-based CARs exhibit promise for clinical indications, as they show enhanced survival and tumor clearance in a mouse model of multiple myeloma and most closely phenocopy a transcriptional signature for enhanced T cell fitness and persistence that was independently identified within two human patient studies.